Melaku Tafese Awulachew*

Food Science and Nutrition Research, Ethiopian Institute of Agricultural Research, Ethiopia

*Corresponding Author: Melaku Tafese Awulachew, Food Science and Nutrition Research, Ethiopian Institute of Agricultural Research, Ethiopia.

Received: June 20, 2022; Published: August 01, 2022

Cardiovascular disease is still the world’s leading cause of death [1]. Dyslipidemia is one of the most important risk factors for cardiovascular disease. Treatment of dyslipidemia with pharmaceutical or lifestyle therapies has been found to reduce cardiovascular disease-related mortality [2,3], emphasizing the relevance of addressing dyslipidemia in the prevention and treatment of cardiovascular disease. Dyslipidemia is caused by a disruption in lipoprotein metabolism, of which dietary fat absorption is a prominent component. Therefore, it is essential to understand how the small intestine absorbs dietary lipids and transport them as lipoproteins, namely chylomicrons and very low-density lipoproteins.

Keywords: Absorption Advance; Apolipoprotein; Lipoprotein; Lipid; Gut; Chylomicron; Very Low-Density Lipoproteins; Lymph; Bile Acid

References

1. WHO (2020)?
2. Shalev V., et al. “Continuation of statin treatment and all-cause mortality: a population-based cohort study”. Archives of Internal Medicine 169 (2009): 260-268.
3. Haglin L., et al. “All-cause mortality of patients with dyslipidemia up to 19 years after a multidisciplinary lifestyle modification programme: a randomized trial”. European Journal of Cardiovascular Prevention and Rehabilitation 18 (2011): 79-85.
4. Cifarelli V., et al. “Editorial: the role of the lymphatic system in lipid and energy metabolism, and immune homeostasis during obesity and diabetes”. Frontiers in Physiology 12 (2021): 652461.
5. Levy E., et al. “From Congenital Disorders of Fat Malabsorption to Understanding Intra-Enterocyte Mechanisms behind Chylomicron Assembly and Secretion”. Frontiers in Physiology 12 (2021): 629222.
6. Nakano T., et al. “Ezetimibe impairs transcellular lipid trafficking and induces large lipid droplet formation in intestinal absorptive epithelial cells”. Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids 1865 (2020): 158808.
7. Kusters DM., et al. “Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy”. The Netherlands Journal of Medicine 68 (2010): 299-303.
8. Fitzpatrick LR and Jenabzadeh P. “IBD and Bile Acid Absorption: Focus on Pre-clinical and Clinical Observations”. Frontiers in Physiology 11 (2020): 564.
9. Vitek L. “Bile acid malabsorption in inflammatory bowel disease”. Inflammatory Bowel Diseases 21 (2015): 476-483.
10. Lo CC and Coschigano KT. “ApoB48 as an Efficient Regulator of Intestinal Lipid Transport”. Frontiers in Physiology 11 (2020): 796.
11. Lo CM., et al. “Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation?” The American Journal of Physiology-Gastrointestinal and Liver Physiology 294 (2008): G344-G352.
12. Trevaskis NL., et al. “Intestinal Lymph Flow, and Lipid and Drug Transport Scale Allometrically from Pre-clinical Species to Humans”. Frontiers in Physiology 11 (2020): 458.
13. McMillan DW., et al. “Effect of Paraplegia on the Time Course of Exogenous Fatty Acid Incorporation into the Plasma Triacylglycerol Pool in the Postprandial State”. Frontiers in Physiology 12 (2021): 626003.
14. Nauli AM and Matin S. “Why do men accumulate abdominal visceral fat?” Frontiers in Physiology 10 (2019): 1486.
15.  

Citation

Citation: Melaku Tafese Awulachew. “Editorial: Dietary Fat".Acta Scientific Nutritional Health 6.9 (2022): 01-03.

Copyright

Copyright: © 2022 Melaku Tafese Awulachew. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.